Dobutamine stress echocardiography for assessing coronary artery disease after transplantation in children  by Larsen, Ranae L et al.
Dobutamine Stress Echocardiography for Assessing Coronary Artery
Disease After Transplantation in Children
RANAE L. LARSEN, MD, FACC, PATRICIA M. APPLEGATE, MD, FACC, DANIEL A. DYAR, MA,
PAULO A. RIBEIRO, MD, FACC, SHARON D. FRITZSCHE, RN, NEDA F. MULLA, MD, FACC,
GIRISH S. SHIRALI, MD, FACC, MICHEAL A. KUHN, MD, FACC, RICHARD E. CHINNOCK, MD,
AND PRAVIN M. SHAH, MD, FACC
Loma Linda, California
Objectives. The purpose of this study was to determine the
feasibility, safety and diagnostic accuracy of dobutamine stress
echocardiography (DSE) for evaluating posttransplant coronary
artery disease (TxCAD) in children, and to determine the fre-
quency of selected cardiac events after normal or abnormal DSE.
Background. Posttransplant coronary artery disease is the most
common cause of graft loss (late death or retransplantation) after
cardiac transplantation (CTx) in children. Coronary angiography,
routinely performed to screen for TxCAD, is an invasive proce-
dure with limited sensitivity. The efficacy of DSE for detecting
atherosclerotic coronary artery disease is established, but is
unknown in children after CTx.
Methods. Of the 78 children (median age 5.7 years, range 3 to
18) entered into the study, 72 (92%) underwent diagnostic DSE by
means of a standard protocol, 4.6 6 1.9 years after CTx. The
results of coronary angiography performed in 70 patients were
compared with DSE findings. After DSE, subjects were monitored
for TxCAD-related cardiac events, including death, retransplan-
tation and new angiographic diagnosis of TxCAD.
Results. No major complications occurred. Minor complica-
tions, most often hypertension, occurred in 11% of the 72 subjects.
The sensitivity and specificity of DSE were 72% and 80%, respec-
tively, when compared with coronary angiography. At follow-up
(21 6 8 months), TxCAD-related cardiac events occurred in 2 of
50 children (4%) with negative DSE, versus 6 of 22 children (27%)
with positive DSE (p < 0.01).
Conclusions. DSE is a feasible, safe and accurate screening
method for TxCAD in children. Positive DSE identifies patients at
increased risk of TxCAD-related cardiac events. Negative DSE
predicts short-term freedom from such events.
(J Am Coll Cardiol 1998;32:515–20)
©1998 by the American College of Cardiology
Posttransplant coronary artery disease (TxCAD) is the leading
cause of death beyond the first year after cardiac transplanta-
tion (CTx), and the most common indication for retransplan-
tation in both children and adults (1,2). Most CTx centers
perform coronary angiography (ANG) annually after CTx to
screen for TxCAD. However, the angiographic appearance of
TxCAD does not correlate well with either pathologic findings
or the functional significance of the disease (3–5). The intimal
hyperplasia found in TxCAD tends to be diffuse and concen-
tric, making changes in the arterial lumen difficult to detect
angiographically. Additionally, ANG is invasive and has risks
of vascular injury and bleeding, especially in young children
(6). A safe, sensitive and noninvasive method for detecting
TxCAD would be invaluable for follow-up of children after
CTx.
Dobutamine stress echocardiography (DSE) has been doc-
umented to safely, accurately and noninvasively detect athero-
sclerotic coronary artery disease (7–9) and determine its
functional and prognostic significance (10–12). DSE, a nonin-
vasive procedure, has important advantages over ANG, includ-
ing lower cost, general availability and avoidance of radiation
exposure. Although DSE has been performed to a limited
extent in adult patients after CTx for surveillance of TxCAD
(13–15), there is little experience with the procedure in trans-
planted or nontransplanted children. The purpose of this study
was to determine the feasibility, safety and diagnostic accuracy
of DSE in assessing TxCAD after CTx in children, and then to
determine the frequency of selected cardiac events after
normal or abnormal DSE.
Methods
Patient selection. Patients were eligible for the study if they
(1) underwent CTx at Loma Linda University Children’s
Hospital and Medical Center between the ages of 1 day and 17
years, (2) received annual follow-up at this institution, (3) were
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at least 3 years of age at the time of the study, and (4) were at
least 1 year after CTx. Patients were excluded if (1) they were
pacemaker-dependent (with limited heart rate response to
pharmacologic manipulation), (2) they had known or sus-
pected rejection, (3) they were known to have severe TxCAD
(because of initial safety concerns), or (4) informed consent
was declined. The study protocol was approved by the Loma
Linda University Institutional Review Board. Written in-
formed consent was obtained from a parent or legal guardian,
and when age-appropriate, from the patient.
Patient population. From November 1985 to December
1996, 292 children underwent cardiac transplantation at Loma
Linda University. By the end of this study, in December 1996,
there were 217 survivors. Of these, 34 were less than three
years of age, 11 were less than one year after transplant, 82
were followed at institutions other than Loma Linda and 5
were pacemaker-dependent. Of the remaining 85 eligible
patients, 78 (92%) were entered into the study. Seven patients
were not studied because parents declined participation. In the
study group, median age at CTx was 2 months (range 4 days to
16.0 years). Median age at the time of DSE was 5.7 years
(range 3.0 to 18.0 years). Studies were performed 4.6 6 1.9
years (range 1.0 to 9.0 years) after CTx.
At the time of DSE, the patients’ immunosuppressive
protocol included cyclosporine (n 5 70), tacrolimus (n 5 2),
azathioprine or methotrexate (n 5 42) and prednisone (n 5
10). Some patients were receiving either a calcium antagonist
(n 5 10) or an angiotensin-converting enzyme inhibiting agent
(n 5 10) for treatment of systemic hypertension. No patient
was receiving beta-adrenergic antagonistic therapy. Medica-
tions were given as per the patient’s usual schedule on the
morning of the test.
The CTx follow-up protocol at Loma Linda University
Children’s Hospital and Medical Center includes annual ANG
beginning one year after CTx. Repeat transplantation is rec-
ommended when TxCAD becomes severe (.75% narrowing)
in any one vessel. Patients with mild or moderate disease
undergo ANG every 6 months.
Dobutamine stress echocardiography. All children
younger than 6 years of age were sedated with chloral hydrate
(60 mg/kg, maximum dose 1,200 mg) orally and midazolam
(1 mg) intravenously for the study. Additional midazolam was
then given as needed for anxiety during the study. Heart rate,
blood pressure and oxygen saturation (by pulse oximetry) were
monitored throughout the study.
Transthoracic echocardiographic imaging was performed
on standard cardiac ultrasound equipment (Hewlett-Packard
Sonos 1000 or 1500 or Acuson 128XP). Parasternal short and
long axes and apical two- and four-chamber views of the left
ventricle were obtained at baseline and during each stage.
Images were recorded on videotape at each stage of dobut-
amine infusion. An on-line analysis system (Nova-Microsonics
ImageVue DCR) was used for acquisition and digital analysis
of images obtained at baseline, low dose, mid-dose and peak
dobutamine dose. The rest and stress echocardiographic im-
ages were arranged in a quad screen display for simultaneous
comparisons.
Dobutamine was begun at an infusion dose of 5 mg/kg/min
intravenously and increased every 3 minutes in 5- to 10-mg/kg/
min increments depending on individual patient response. The
study was terminated if the patient (1) reached a maximum
dobutamine dose of 50 mg/kg/min; (2) attained 75% of age-
predicted (220 minus age in years) maximal heart rate; (3)
developed new wall motion abnormalities in any segment; (4)
became hypotensive, with a decrease in systolic blood pressure
to ,80 mm Hg; (5) became hypertensive, with an increase in
systolic blood pressure to .180 mm Hg or diastolic blood
pressure .100 mm Hg; (6) developed sustained supraventric-
ular or ventricular arrhythmias, or (7) developed $2-mm ST
segment depression on the 12-lead electrocardiogram. Al-
though many DSE protocols recommend that a peak heart rate
of 85% of age-predicted value be attained, a peak heart rate of
75% age-predicted value was chosen because of concerns for
safety in this young population and known chronotropic in-
competence secondary to cardiac denervation after CTx
(16,17).
A cardiologist experienced in DSE was present during the
performance of each study and interpreted the results. This
investigator had no knowledge of the patients’ clinical history
or previous ANG. A normal response to dobutamine was
defined as a progressive increase in myocardial wall thickening,
wall motion, and left ventricular ejection fraction, and im-
provement in any resting wall motion abnormalities during
dobutamine infusion. An abnormal response to dobutamine,
indicating possible ischemia, was defined as a reduction in
myocardial wall thickening or wall motion, failure of a resting
wall motion abnormality to improve or failure of the ejection
fraction to increase during dobutamine infusion. Specific qual-
itative descriptions of new wall motion abnormalities or other
dobutamine-induced abnormalities were noted in a written
report.
Dobutamine stress electrocardiography. Standard 12-lead
electrocardiograms were recorded in all patients at rest, at the
end of each dobutamine stage and during recovery. Electro-
cardiograms were monitored for rate, rhythm and for evidence
of ischemia. The tracings were considered abnormal and
suspicious for ischemia if there was a .1.5-mm ST segment
depression compared with baseline.
Coronary angiography. Cineangiograms of each coronary
artery in two orthogonal planes were obtained using the
Judkins’ technique through a percutaneous femoral artery
approach. The left coronary artery was filmed in caudally
angulated left anterior oblique and cranially angulated right
Abbreviations and Acronyms
ANG 5 coronary angiography
CTx 5 cardiac transplantation
DSE 5 dobutamine stress echocardiography
TxCAD 5 posttransplant coronary artery disease
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anterior oblique views, followed by a second injection using
cranially angulated left anterior oblique and caudally angu-
lated right anterior oblique projections. The right coronary
artery was filmed in the right anterior oblique and left anterior
oblique projections. A coronary vasodilator was not routinely
given before contrast injection.
Seventy of the 72 children (97%) undergoing DSE under-
went ANG and formed the basis for comparisons between
results of DSE and ANG. In 2 children, the operator was
unable to obtain arterial access. DSE was performed the same
day as ANG in 40 patients. In the remainder, DSE was
performed no more than 90 days before or after ANG.
Two investigators experienced in the interpretation of ANG
performed visual qualitative assessment after CTx, one per-
forming the study and a second from review of the cineangio-
grams alone. These investigators had no knowledge of the
results of the DSE or of the results of previous ANG. If there
was a difference in interpretation between the two investiga-
tors, the cineangiograms were reviewed by a group of experi-
enced pediatric cardiologists and pediatric cardiothoracic sur-
geons. Evidence of TxCAD was recorded and graded for
severity and distribution. Mild TxCAD was defined as ,50%
narrowing of any coronary artery branch. Moderately severe
TxCAD was defined as 50% to 75% narrowing in any coronary
artery branch. Severe TxCAD was defined as .75% narrowing
of any coronary artery branch. Angiograms were also reviewed
for loss of third-order branching and for the presence of
myocardial bridging.
Statistical analysis. The sensitivity and specificity of DSE
for detection of TxCAD was determined using established
formulas. Results for continuous variables in the text and
figures are expressed as mean 6 SD. Student’s t test was used
to analyze differences between mean values. A chi-square test
was used to compare proportions. Kaplan-Meier life-table
estimates of cardiac event-free survival were used to summa-
rize follow-up data. A p value ,0.05 was considered signifi-
cant.
Results
Feasibility. Written informed consent was obtained for 78
children. Six (8%) were unable to be studied or were judged to
have diagnostically inadequate studies. Of these six, dobut-
amine infusion was not begun in four children. Two children
had poor acoustic images at baseline. One child had baseline
hypertension .180/100 mm Hg. One patient had severe base-
line wall motion abnormalities, and at the discretion of the
monitoring cardiologist, the study was discontinued before
dobutamine infusion was begun. This child was subsequently
found to have severe angiographic TxCAD. Dobutamine infu-
sion was terminated before a complete study could be per-
formed in two other patients who developed severe hyperten-
sion at dobutamine doses of 5 mg/kg/min. Overall, 92% of the
78 children in whom consent was obtained underwent a
technically diagnostic DSE.
Safety. Reasons for terminating the dobutamine infusion
included (1) attainment of the target heart rate in 45 (63%)
patients, (2) reaching the maximal dobutamine dose in 15
(21%) patients, (3) new or worsening wall motion abnormali-
ties in 10 patients (14%), and (4) development of hypertension
in 2 patients (3%).
No patient developed major complications during dobut-
amine infusion. Minor adverse effects were noted in 8 of 72
patients (11%). Hypertension was the most common adverse
effect, occurring in 3 of 72 patients (4%). Blood pressure
returned to normal within 15 minutes in all patients with no
treatment, other than discontinuing the dobutamine. One
patient became mildly hypotensive after the dobutamine infu-
sion was discontinued. Two patients developed occasional (,3
complexes/min) supraventricular ectopic beats during dobut-
amine infusion. One patient complained of mild headache. No
patient developed ventricular arrhythmias, supraventricular
tachycardia, chest pain, dyspnea, nausea, vomiting or dizziness
during dobutamine infusion or the recovery period.
Hemodynamic response. The peak dobutamine dose was
30 6 10 mg/kg/min. Resting and peak dobutamine stress
hemodynamic data are summarized in Table 1. The target
heart rate (75% of the age-predicted value) was attained in
63% of patients. Systolic blood pressure increased 24% during
dobutamine infusion. Diastolic blood pressure did not change
significantly. The heart rate–systolic blood pressure product
doubled during dobutamine infusion.
Dobutamine stress electrocardiography. The rhythm was
sinus throughout the entire study in all 72 patients. Forty-six of
the 72 patients (64%) had either right ventricular conduction
delay or complete right bundle branch block on the baseline
electrocardiogram. No patient had electrocardiographic
changes with dobutamine infusion that met the criteria for
ischemia. One patient developed ST-segment depression of
1 mm in leads V5 and V6. This patient otherwise had a normal
response to dobutamine and normal ANG.
Comparison of dobutamine stress echocardiography and
coronary angiography. Twenty-two of 72 patients (31%) had
new wall motion abnormalities during dobutamine infusion,
indicating possible ischemia. Coronary angiography demon-
strated evidence of TxCAD in 14 of 70 children (20%).




Heart rate (beats/min) 100 6 16 159 6 18*
Range 57–135 96–193
% predicted for age 75% 6 8%
Systolic blood pressure (mm Hg) 105 6 12 130 6 21*
Range 81–138 96–188
Diastolic blood pressure (mm Hg) 61 6 14 68 6 17
Range 31–92 31–105
Heart rate–blood pressure product 10.3K 6 2.9K 20.1K 6 3.8K*
Range 5.7K–13.7K 13.0K–30.8K
*p , 0.001. Data presented are mean value (range) 6 SD.
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Comparisons of test results were made in the 70 patients who
underwent both ANG and DSE. Dobutamine stress echocar-
diographic results were positive in 10 of 14 patients with
angiographic TxCAD (sensitivity 71%) and negative in 45 of 56
patients with normal ANG (specificity 80%). Angiographic
TxCAD was present in 10 of 22 patients (45%) with positive
DSE (positive predictive value), and absent in 44 of 48 (92%)
of patients with normal DSE (negative predictive value). The
location and severity of the echocardiographic findings in the
patients with abnormal ANG are described in Table 2.
There were no significant differences in age at CTx (median
2.0 vs. 2.4 months), age at DSE (median 5.4 vs. 6.0 years) or
time since CTx (4.4 6 1.8 vs. 4.8 6 1.9 years) between the
groups of patients with normal or abnormal DSE.
Follow-up data. The 72 patients who underwent DSE have
been followed 21 6 8 months since DSE (range 6 to 35
months). The four patients with positive ANG, but normal
DSE (“false” negative studies), have subsequently had normal
ANG 9 to 15 months after DSE. Review of the initial ANG
suggested that the arteries interpreted as narrowed were areas
of spasm rather than TxCAD. These four patients are alive and
without evidence of TxCAD 29 to 34 months after initial ANG
and DSE. The remaining 10 patients with both positive ANG
and DSE have had confirmation of the coronary lesions by
repeat angiographic or pathologic evaluation after death or
retransplantation.
Figure 1 compares the freedom from death, retransplanta-
tion for TxCAD or new angiographic evidence of TxCAD after
normal versus abnormal DSE. At follow-up, 4% of the 50
patients with normal DSE had TxCAD-related late cardiac
events compared with 27% of patients with abnormal DSE.
Discussion
Transplant coronary artery disease. Posttransplant coro-
nary artery disease is an important cause of morbidity and
mortality after CTx in children, occurring in 12% to 24% of
recipients at 1 year and in 18% to 43% of recipients at 3 years
after CTx (18–22). At our institution, the incidence of TxCAD
was 23% seven years after CTx in patients transplanted during
infancy for hypoplastic left heart syndrome (23). Once TxCAD
is evident angiographically in adults or children, short-term
mortality is high (24,25), making surveillance a high priority.
Risk factors associated with TxCAD in children have not
been completely defined. A study of 206 children who under-
went transplantation at our institution who survived more than
one year indicated that only severe rejection beyond the first
post-CTx year and the number of rejections in the first six
months after CTx were independent predictors of TxCAD
(25). Gender, age at CTx, lipid status, infection history and
cytomegalovirus infection were not independent risk factors
for the development of TxCAD.
Because of surgical cardiac denervation at the time of CTx,
angina rarely occurs as a warning symptom of myocardial
ischemia. Sudden death is often the first evidence of TxCAD.
Many institutions perform yearly ANG to monitor for the
development and progression of TxCAD, although the relative
insensitivity of ANG compared with pathologic or intravascu-
lar ultrasound is well recognized (4,5,26). Additional disadvan-
tages of ANG include the risk of vascular injury, particularly in
children (27,28), exposure to radiation and the cost of the
procedure.
Dobutamine stress echocardiography. This procedure has
been used to a limited extent in adults after CTx, with a
sensitivity and specificity of 83% to 95% and 55% to 91%,
respectively, when compared with ANG (13–15). Spes and
coinvestigators (14) reported the sensitivity of DSE to be 79%
Figure 1. Kaplan-Meier event-free curves for posttransplant coronary
artery disease (TxCAD)–related cardiac events, including death, re-
transplantation and the new development of angiographic TxCAD
according to positive or negative dobutamine stress echocardiography
(DSE). Each plot represents the proportion of patients remaining
event free.
Table 2. Coronary Angiographic and Dobutamine Stress





Location and Severity of Coronary
Angiography Abnormalities
1 Apical septum Diffuse narrowing of LCA and
RCA (mild)
2 Anterior septum and LV apex;
apical anterior wall
Mid-LAD (mild)
3 Anterior and posterior septum Distal LAD (moderate)
4 Mid- and apical septum;
inferoapical segments
Cx (moderate); mid- and distal
LAD (severe); RCA
(moderate); first and second
diagonals (moderate)
5 Posterior-inferior wall Cx (moderate); distal LAD (mild)
6 Inferior wall Cx (moderate)




Cx (moderate); LAD (moderate);
RCA (moderate)
9 Anterior septum Mid- and distal LAD (moderate);
Diffuse narrowing of RCA
(mild)
10 Anterior septum; anterior
apex
Cx (moderate); LAD (mild)
Cx 5 circumflex coronary artery; DSE 5 dobutamine stress echocardiogra-
phy; LAD 5 left anterior descending coronary artery; LCA 5 left coronary
artery; RCA 5 right coronary artery
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when compared with intracoronary ultrasound. Derumeaux et
al (13) advocated that DSE be performed as routine surveil-
lance for TxCAD in adult patients after CTx. Studies have also
suggested that DSE predicts risk of cardiac events in adult CTx
recipients (29,30). Akosah and coinvestigators found that after
24 months of follow-up, 33% of patients with positive DSE had
experienced TxCAD-related cardiac events.
Dobutamine stress echocardiography in children. Experi-
ence with DSE in children is limited (31,32). Kimball and Witt
(32) performed 74 DSE studies in 46 children, 10 of whom
underwent the study after CTx. Four of the 10 patients had
evidence of dobutamine-induced ischemia (33). All four of
these patients were documented to have TxCAD at follow-up.
Present study. Feasibility. Our study shows that DSE is
feasible in most children after CTx. Because the quality of the
echocardiographic images is important for accurate interpre-
tation of wall motion abnormalities (34), the smaller size and
therefore better imaging windows of children may offer an
advantage. The cooperation of younger patients was facilitated
by our use of sedation. In older children, we found that a clear,
simple explanation of the procedure usually resulted in their
cooperation and tolerance of the procedure.
Safety. The most common adverse effect was hypertension,
which resolved after dobutamine was discontinued. No com-
plications secondary to ischemia occurred, even in children
with angiographic TxCAD. By study design, patients with
known severe (.75% narrowing) TxCAD were excluded.
Thus, safety of DSE in patients with severe TxCAD cannot be
addressed by this study.
Diagnostic accuracy. Compared with ANG performed near
the time of DSE, the sensitivity of DSE in our study was similar
to that reported in adult patients with atherosclerotic coronary
artery disease. Because the four patients with “false negative”
DSE were ultimately determined to have coronary artery
spasm rather than TxCAD, all patients with angiographic
evidence of TxCAD had an abnormal DSE. Additionally,
approximately one fourth of patients with “false positive” DSE
died suddenly and had coronary artery disease at pathologic
evaluation.
Previous observers have emphasized the importance of
experience and competence in interpreting stress echocardio-
grams (35). Because coronary artery disease is relatively un-
common in children, many pediatric cardiologists may be
unaccustomed to assessing echocardiographic ischemia-
induced wall motion abnormalities. Assistance from practitio-
ners experienced in the performance and interpretation of
these studies can be the key to accurate interpretation.
Prognostic value. The most important contribution of DSE
in this population may be its identification of children at
increased risk for the development of TxCAD and its compli-
cations. By two years after abnormal DSE, graft loss, either by
death or repeat CTx, occurred in 40% of patients. In contrast,
patients with normal DSE had only a 4% risk of TxCAD-
related cardiac events in the same time period. The experience
in two children with both normal ANG and DSE 15 to 18
months before dying suddenly of TxCAD, however, empha-
sizes the importance of systematic monitoring of patients after
CTx.
We propose that after CTx, children undergo annual DSE
to screen for TxCAD. An experienced echocardiographer
should interpret the studies. Coronary angiography may be
performed less frequently, barring a late rejection episode or
clinical symptoms suggestive of coronary artery disease. This
may result in reduced morbidity and expense of follow-up after
CTx. Children with abnormal DSE, however, should undergo
an invasive study such as ANG or intravascular ultrasound.
Our institution has changed its CTx follow-up protocol to
include yearly DSE, and ANG every other year, beginning one
year after CTx. Follow-up is needed to determine the impact of
this change on patient morbidity, survival and cost.
Study limitations. This study was limited by our use of
qualitative ANG as the reference standard for comparison of
the results of DSE. Although it is the method most often used
for assessment of TxCAD, ANG is an imperfect standard
because of its recognized limitations in sensitivity. Intracoro-
nary ultrasound, which may be the new gold standard for the
detection of TxCAD, is expensive, invasive and has significant
limitations in small vessels (36,37). DSE is noninvasive and can
usually visualize all segments of the myocardium.
DSE is limited by its reliance on the subjective analysis of
images by the observer (38,39). However, other investigators
have reported interobserver variability to be low, with interob-
server agreement of .90% (40,41). Additionally, the reliability
of DSE when interpreted by experienced observers has been
established by several large studies (38).
Conclusions. We conclude that DSE safely and noninva-
sively provides accurate diagnostic and prognostic information
regarding TxCAD in children after CTx. Patients with abnor-
mal DSE have a high likelihood of TxCAD-related cardiac
events in the 24 months after DSE. Patients with normal DSE
have an excellent prognosis in the same time period. We
propose that DSE be performed yearly in children after CTx
for surveillance of TxCAD.
We are indebted to the nurses of the Pediatric Observation Unit at Loma Linda
University Children’s Hospital for their patient care and assistance during DSE
and to Stephen Ashwal, MD and Joyce Johnston, RN for review of the
manuscript.
References
1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ. The Registry of the
International Society for Heart and Lung Transplantation: fourteenth official
report–1997. J Heart Lung Transplant 1997;16:691–712.
2. Bieber CP, Hunt SA, Schwinn DA. Complications in long-term survivors of
cardiac transplantation. Transplant Proc 1981;8:207–11.
3. Everett JP, Hershberger RE, Ratkovec RM, et al. The specificity of normal
qualitative angiography in excluding cardiac allograft vasculopathy. J Heart
Lung Transplant 1994;13:142–9.
4. Arbustini E, Roberts WC. Morphologic observations in the epicardial
coronary arteries and their surroundings late after cardiac transplantation
(allograft vascular disease) Am J Cardiol 1996;78:814–20.
5. Johnson DE, Alderman EL, Schroeder JS, et al. Transplant coronary artery
disease: histopathologic correlations with angiographic morphology. J Am
Coll Cardiol 1991;17:449–57.
519JACC Vol. 32, No. 2 LARSEN ET AL.
August 1998:515–20 DOBUTAMINE ECHOCARDIOGRAPHY AFTER TRANSPLANTATION
6. Mulla NF, Loewen NK, Beeson WL, et al. Endomyocardial biopsies in
pediatric cardiac transplant recipients: difficulties, complications, and out-
come [abstract]. J Invest Med 1996;44:122A.
7. Sawada SG, Segar DS, Ryan T, et al. Echocardiographic detection of
coronary artery disease during dobutamine infusion. Circulation 1991;83:
1605–14.
8. Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography
for detection and assessment of coronary artery disease. J Am Coll Cardiol
1992;19:1203–11.
9. Segar DS, Brown SE, Sawada SG, Ryan T, Feigenbaum H. Dobutamine
stress echocardiography: correlation with coronary lesion severity as deter-
mined by quantitative angiography. J Am Coll Cardiol 1992;19:1197–1202.
10. Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognos-
tic value of dobutamine stress echocardiography in patients with left
ventricular dysfunction. J Am Coll Cardiol 1996;27:132–9.
11. Marcovitz PA, Shayna V, Horn RA, Hepner A, Armstrong WF. Value of
dobutamine echocardiography in determining the prognosis of patients with
known or suspected coronary artery disease. Am J Cardiol 1996;78:404–8.
12. Greco CA, Salustri A, Seccareccia F, et al. Prognostic value of dobutamine
echocardiography early after uncomplicated acute myocardial infarction: a
comparison with exercise electrocardiography. J Am Coll Cardiol 1997;29:
261–7.
13. Derumeaux G, Redonnet M, Mouton-Schleifer D, et al. Dobutamine stress
echocardiography in orthotopic heart transplant recipients. J Am Coll
Cardiol 1995;25:1665–72.
14. Spes CH, Mudra H, Schnaack SD, et al. Dobutamine stress echocardiogra-
phy for noninvasive diagnosis of cardiac allograft vasculopathy; a comparison
with angiography and intravascular ultrasound. Am J Cardiol 1996;78:168–
74.
15. Akosah KO, Mohanty PK, Funai JT, et al. Noninvasive detection of
transplant coronary artery disease by dobutamine stress echocardiography.
J Heart Lung Transplant 1994;13:1024–38.
16. Gullestad L, Haywood G, Ross H, et al. Exercise capacity of heart transplant
recipients: the importance of chronotropic incompetence. J Heart Lung
Transplant 1996;15:1075–83.
17. Mulla NF, Feenstra LH, Johnston JK, et al. Exercise capacity following
neonatal cardiac transplantation for hypoplastic left heart syndrome [ab-
stract]. J Am Coll Cardiol 1996;27:341A.
18. Braunlin EA, Hunter DW, Canter CE, et al. Coronary artery disease in
pediatric cardiac transplant recipients receiving triple-drug immunosuppres-
sion. Circulation 1991;84:III-303–III-9.
19. Pahl E, Zales VR, Fricker FJ, Addonizio LJ. Posttransplant coronary artery
disease in children: a multicenter national survey. Circulation 1994;90:II-56–
II-60.
20. Berry GJ, Rizeq MN, Weiss LM, Billingham ME. Graft coronary disease in
pediatric heart and combined heart-lung transplant recipients: a study of
fifteen cases. J Heart Lung Transplant 1993;12:S309–S19.
21. Canter CE, Saffitz JE, Moorhead S, Gutierrez FR, Bolman RM, Spray TL.
Early results after pediatric cardiac transplantation with triple immunosup-
pressive therapy. Am J Cardiol 1993;71:971–5.
22. Addonizio LJ, Hsu DT, Douglas JF, et al. Decreasing incidence of coronary
disease in pediatric cardiac transplant recipients using increased immuno-
suppression. Circulation 1993;88:II-224–II-9.
23. Razzouk AJ, Chinnock RE, Gundry SR, et al. Transplantation as a primary
treatment for hypoplastic left heart syndrome: intermediate-term results.
Ann Thorac Surg 1996;62:1–8.
24. Pahl E, Fricker FJ, Armitage J, et al. Coronary arteriosclerosis in pediatric
heart transplant survivors: limitation of long-term survival. J Pediatr 1990;
116:177–83.
25. Mulla NF, Johnston JK, VanderDussen L, et al. Early re-transplantation for
post transplant coronary artery disease in children [abstract]. J Heart Lung
Transplant 1997;16:71.
26. St. Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in
cardiac transplant recipients: in vivo evidence of “angiographically silent”
intimal thickening. Circulation 1992;85:979–87.
27. Stanger P, Heymann MA, Tarnoff H, et al. Complications of cardiac
catheterization of neonates, infants and children. Circulation 1974;50:595–
608.
28. Lock JE. Manual techniques of cardiac catheterization: vessel entry and
catheter manipulation. In: Lock JE, Keane JF, Fellows KE, editors. Diag-
nostic and Interventional Catheterization in Congenital Heart Disease.
Boston, MA: Martinus Nijhoff, 1987:11–31.
29. Akosah KO, Olsovsky M, Kirchberg D, Salter D, Mohanty PK. Dobutamine
stress echocardiography predicts cardiac events in heart transplant patients.
Circulation 1996;94:II-283–II-8.
30. Lewis JF, Selman SB, Murphy JD, Mills RM, Geiser EA, Conti CR.
Dobutamine echocardiography for prediction of ischemic events in heart
transplant recipients. J Heart Lung Transplant 1997;16:390–3.
31. Noto N, Ayusawa M, Karasawa K, et al. Dobutamine stress echocardiogra-
phy for detection of coronary artery stenosis in children with Kawasaki
disease. J Am Coll Cardiol 1996;27:1251–6.
32. Kimball TR, Witt SA, Daniels SR. Dobutamine stress echocardiography in
the assessment of suspected myocardial ischemia in children and young
adults. Am J Cardiol 1997;79:380–4.
33. Kimball TR, Witt SA. The prognostic significance of a positive dobutamine
stress echocardiogram in pediatric heart transplant patients [abstract]. J Am
Soc Echo 1996;9:369.
34. Hoffman R, Lethen H, Marwick T, et al. Analysis of interinstitutional
observer agreement in interpretation of dobutamine stress echocardiograms.
J Am Coll Cardiol 1996;27:330–6.
35. Picano E, Lattanzi F, Orlandini A, Marini C, L’Abbate A. Stress echocar-
diography and the human factor: the importance of being expert. J Am Coll
Cardiol 1991;17:666–9.
36. Rickenbacher PR, Pinto FJ, Chenzbraun A, et al. Incidence and severity of
transplant coronary artery disease early and up to 15 years after transplan-
tation as detected by intravascular ultrasound. J Am Coll Cardiol 1995;25:
171–7.
37. Tuzcu EM, DeFranco AC, Goormastic M, et al. Dichomatous pattern of
coronary atherosclerosis 1 to 9 years after transplantation: insights from
systematic intravascular ultrasound. J Am Coll Cardiol 1996;27:839–46.
38. Geleijnse ML, Fioretti PM, Roelandt JRT. Methodology, feasibility, safety
and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll
Cardiol 1997;30:595–606.
39. Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiog-
raphy in detecting coronary artery disease. Am J Cardiol 1992;69:1269–73.
40. Previtali M, Lanzarini L, Lefiveau R, et al. Comparison of dobutamine stress
echocardiography, dipyridamole stress echocardiography and exercise stress
testing for diagnosis of coronary artery disease. Am J Cardiol 1993;72:865–
70.
41. Cohen JL, Ottenweller JE, George AK, Duvvuri S. Comparison of dobut-
amine and exercise echocardiography for detecting coronary artery disease.
Am J Cardiol 1993;72:1226–31.
520 LARSEN ET AL. JACC Vol. 32, No. 2
DOBUTAMINE ECHOCARDIOGRAPHY AFTER TRANSPLANTATION August 1998:515–20
